端粒酶活性检测联合癌胚抗原、CA19—9对良恶性胸水的鉴别诊断价值

Diagnostic significance of telomerase activity combined with carcinoembryonic antigen and CA19-9 for differentiating benign and malignant pleural effussion

目的探讨端粒酶活性联合癌胚抗原（CEA）、CA19-9在鉴别良、恶性胸水中的价值。方法入选58例胸水患者，用改良的端粒重复序列扩增一酶联免疫吸附试验法检测胸水中脱落细胞端粒酶活性，并测定胸水CEA、CA19—9。结果恶性胸水中端粒酶活性检出阳性率为85．7％。恶性胸水患者中端粒酶活性、CEA、CA19—9测定结果均明显高于良性胸水患者（P〈0．01）。联合端粒酶、CEA、CA19—9共同检测，则敏感性为0．971，特异性为1．000。结论端粒酶在诊断恶性胸水和鉴别良、恶性胸水中具有重要的价值，联合CEA、CA19—9对良、恶性胸水鉴别诊断意义更大。

Objective To investigate the diagnostic significance of telomerase activity combined with carcinoembryonic antigen （CEA）and CA19-9 for differentiating benign and malignant pleural effussion. Methods Telomerase activity, CEA and CA19-9 in pleural effussion from 58 cases were detected by the technique of i＇mproved telomeric repeat amplification protocol-enzyme linked immunosorbent assay. Results The positive rate of telomerase activity in malignant pleural effussion was 85.7 %. The telomerase activity,CEA and CA19-9 in malignant pleural effussion were significantly higher than those in benign pleural effussion（ P 〈0.01 ）. The sensitivity and specificity of detecting tetomerase activity combined with CEA and CA19-9 were 0. 971 and 1. 000, respectively. Conclusions Telomerase assay is useful in differentiating malignant and benign pleural effussion, and will be more significant if combined with CEA and CA19-9.